Don't waste your time Shellbell. Steven never said the ptx-100...

Don't waste your time Shellbell.

Steven never said the ptx-100 trial would start in September.

What did happen was, via a video conference with Professor Miles Prince...Miles stated that he hoped to have regulatory approval and be ready by late September...Steven then, with jest jokingly said early September was his preference.

Any director or reasonably astute business person or investor would understand indicative timelines.

Secondly they would understand the difference between direct failures by management and the effect of greater macro conditions.

If September was such a line in the sand, why still invested? Why harping after a few positive posts this morning? It's as if they were looking to turn the sentiment negative? Perhaps fits into their agenda better?

These are very complicated drugs, they require multiple ingredients and can only be manufactured in very select/qualified environments.

Unless someone has picked up the phone to Steven & asked for an elaboration on the exact extenuating circumstances specific to the delays of PTX-100 it's just huff and puff with little consideration other than 'the buck stops here' rhetoric.

Perhaps they applied the same logic to Alan Joyce at Qantas during lockdown? Why weren't the planes in the sky Mr Joyce? The bucks stops at you!

I don't think so.

You would never as a CEO order an extended trial quantity of ptx-100 until you had studied the completed readout of the phase 1B trial...So any order would have been placed around the time the market was aware of the 1B basket trial success...No board would risk the huge expense of a lead order of a drug only to bin it if the readout was negative...Secondly logistical/supply issues are a fast moving problem eg. They might not have been a problem in March/April but June/July may have looked extremely different for biotech companies and pharma grade manufacturers.

The delays are now behind us...So we should either put them behind or reconsider one's investment.

Speaking to an oncologist today at Peter Mac, her first expression of opinion on CAR-T therapies was its current limitations to target solid tumours...OmniCar can target solid tumours & it's all going to happen under the roof of the Peter MacCallum in the coming months and years.